0R15 8539.0 2.1534% 0R1E 8600.0 3.3654% 0M69 None None% 0R2V 190.25 -0.1312% 0QYR 1345.5 2.0871% 0QYP 424.0 0.5931% 0LCV 146.6464 -1.3147% 0RUK None None% 0RYA 1631.0 -0.6094% 0RIH 171.3 0.9131% 0RIH 174.9 2.1016% 0R1O 186.0 9820.0% 0R1O None None% 0QFP None None% 0M2Z 298.3 -0.6495% 0VSO None None% 0R1I None None% 0QZI 474.5 0.6363% 0QZ0 220.0 0.0% 0NZF None None%
Last update at 2024-05-16T15:35:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2019-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2019-07-31 |
| Income before tax | -41.64200M | -29.19400M | -21.34300M | -18.05400M | -11.13200M |
| Minority interest | - | - | - | - | - |
| Net income | -39.54000M | -26.37400M | -18.89100M | -15.61500M | -9.68300M |
| Selling general administrative | 2.29M | 8.14M | 7.32M | 10.40M | 8.46M |
| Selling and marketing expenses | 11.23M | 8.14M | 7.32M | - | - |
| Gross profit | 7.24M | 2.02M | 2.18M | 4.07M | 3.22M |
| Reconciled depreciation | 3.01M | 2.38M | 2.15M | - | 2.10M |
| Ebit | -27.82000M | -29.08300M | -19.33500M | -12.72635M | -11.18300M |
| Ebitda | -25.86900M | -26.69000M | -17.35500M | - | -9.08100M |
| Depreciation and amortization | 1.95M | 2.39M | 1.98M | - | 2.10M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -27.82000M | -29.08300M | -19.33500M | -18.02900M | -11.18300M |
| Other operating expenses | 37.47M | 32.02M | 22.97M | - | 15.31M |
| Interest expense | 2.70M | 0.13M | 0.09M | 0.00000M | 0.05M |
| Tax provision | -2.10200M | -2.82000M | -2.45200M | -2.43900M | -1.44900M |
| Interest income | 0.09M | 0.02M | 0.04M | 0.03M | 0.05M |
| Net interest income | -2.61000M | -0.11100M | -0.05000M | - | 0.05M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -2.10200M | -2.82000M | -2.45200M | -1.72165M | -1.44900M |
| Total revenue | 9.65M | 2.94M | 3.64M | 5.51M | 4.12M |
| Total operating expenses | 35.06M | 31.10M | 21.52M | - | 14.40M |
| Cost of revenue | 2.41M | 0.92M | 1.46M | 1.44M | 0.91M |
| Total other income expense net | -13.82200M | -0.11100M | -2.00800M | - | 0.05M |
| Discontinued operations | - | 0.06M | 0.06M | -2.49400M | 0.06M |
| Net income from continuing ops | -39.54000M | -26.37400M | -18.89100M | - | -9.68300M |
| Net income applicable to common shares | - | -26.31600M | -18.89100M | -11.02235M | -9.68300M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2019-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2019-07-31 |
| Total assets | 92.65M | 47.00M | 67.46M | 28.41M | 25.73M |
| Intangible assets | 12.09M | 6.39M | 7.10M | 7.97M | 12.53M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | 8.36M | 5.09M | - | - |
| Total liab | 74.21M | 5.78M | 5.53M | 2.60M | 2.29M |
| Total stockholder equity | 18.44M | 41.22M | 61.93M | 25.81M | 23.44M |
| Deferred long term liab | - | 6.05M | 6.87M | 7.93M | - |
| Other current liab | 39.10M | 0.35M | 2.40M | 0.26M | - |
| Common stock | 26.68M | 25.47M | 25.34M | 17.59M | 11.69M |
| Capital stock | 26.68M | 25.39M | 25.27M | - | - |
| Retained earnings | -65.99700M | -34.09300M | -12.86100M | 2.92M | 7.06M |
| Other liab | - | - | - | - | - |
| Good will | 14.23M | 1.54M | 2.31M | 3.83M | - |
| Other assets | - | 6.05M | 6.87M | 7.93M | - |
| Cash | 41.78M | 26.19M | 27.89M | 8.79M | 6.51M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 67.61M | 4.37M | 3.78M | 1.96M | 2.29M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -17.93800M | -24.48800M | -25.85200M | - | - |
| Short term debt | 20.09M | 0.29M | 0.29M | - | - |
| Short long term debt | 18.73M | - | - | - | - |
| Short long term debt total | 23.84M | 1.70M | 2.04M | - | - |
| Other stockholder equity | 57.75M | 49.84M | 49.45M | -1.65200M | 0.17M |
| Property plant equipment | - | 4.34M | 4.79M | 3.08M | 2.64M |
| Total current assets | 55.55M | 34.74M | 53.25M | 13.53M | 10.56M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 33.30M | 59.38M | 21.94M | 10.90M |
| Short term investments | - | - | 20.02M | - | - |
| Net receivables | 5.58M | 4.33M | 4.06M | 3.69M | 3.87M |
| Long term debt | - | - | - | - | - |
| Inventory | 1.68M | 0.19M | 0.25M | 0.16M | 0.18M |
| Accounts payable | 8.42M | 3.73M | 3.49M | 0.70M | 2.29M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 25.34M | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 2.98M | 7.92M | -0.00100M | - | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 37.10M | 12.27M | 14.21M | - | - |
| Capital lease obligations | 5.11M | 1.70M | 2.04M | - | - |
| Long term debt total | - | - | - | 0.65M | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2019-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2019-07-31 |
| Investments | -25.04200M | 18.70M | -20.23400M | -20.23400M | -20.23400M |
| Change to liabilities | 0.00000M | 0.46M | 1.63M | 0.06M | 0.59M |
| Total cashflows from investing activities | - | 18.70M | -21.89900M | -1.78376M | -2.01300M |
| Net borrowings | - | -0.29000M | -0.25500M | -0.15600M | -0.15600M |
| Total cash from financing activities | 56.90M | 0.23M | 51.65M | 13.49M | 10.92M |
| Change to operating activities | - | - | - | - | - |
| Net income | -39.18900M | -26.31600M | -18.89100M | -11.02235M | -9.68300M |
| Change in cash | 15.59M | -1.70300M | 19.11M | 2.52M | 1.29M |
| Begin period cash flow | 26.19M | 27.89M | 8.79M | 6.51M | 5.22M |
| End period cash flow | 41.78M | 26.19M | 27.89M | 8.79M | 6.51M |
| Total cash from operating activities | -16.43200M | -20.50600M | -10.64200M | -9.18705M | -7.62400M |
| Issuance of capital stock | 9.49M | 0.52M | 54.86M | - | 10.92M |
| Depreciation | 3.01M | 2.38M | 2.15M | 1.22M | 2.10M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 0.05M | 0.01M | -0.09100M | 0.02M | 0.00600M |
| Change to account receivables | - | -1.59900M | -0.81400M | -0.58235M | -1.26500M |
| Sale purchase of stock | - | - | - | 19.33M | - |
| Other cashflows from financing activities | 47.42M | -0.29000M | -3.21500M | -2.96000M | -2.01300M |
| Change to netincome | 15.88M | 4.61M | 5.37M | -0.44612M | 0.62M |
| Capital expenditures | 0.76M | 1.31M | 1.67M | 0.44M | 2.01M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 3.87M | -1.13000M | 0.72M | - | -0.66800M |
| Stock based compensation | 7.49M | 5.08M | 3.11M | - | 0.44M |
| Other non cash items | 8.38M | 0.12M | 0.05M | - | 0.18M |
| Free cash flow | -17.19100M | -21.82000M | -12.30700M | - | -9.63700M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (GBP) | Price (GBP) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AVCT Avacta Group PLC |
-0.75 1.69% | 43.50 | - | - | 23.19 | 14.78 | 20.75 | -10.4566 |
| ONT Oxford Nanopore Technologies Ltd |
-2.0 1.76% | 111.50 | - | - | 10.88 | 2.75 | 8.77 | -16.7946 |
| GNS Genus PLC |
-14.0 0.74% | 1880.00 | 42.59 | 25.71 | 2.08 | 2.46 | 2.31 | 16.39 |
| PRTC PureTech Health plc |
-0.5 0.22% | 222.00 | - | - | 35.55 | 1.04 | 95.87 | -4.5333 |
| BVXP Bioventix |
- -% | 4375.00 | 27.22 | 25.97 | 18.06 | 18.93 | 17.37 | 21.69 |
Avacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms. The company develops AVA6000, FAPa-activated doxorubicin that is in Phase I clinical trial for treating locally advanced or metastatic-selected solid tumors; AVA3996, a tumor-targeted proteasome inhibitor based on bortezomib; AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing LR19128 PD-L1 XT; and collaboration and license agreement with Avacta and Daewoong Pharmaceutical Co. Ltd. for developing AFX-001 for solid organ transplant and graft vs host Disease, and AFX-002 for multiple sclerosis. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
Thorp Arch Estate, Wetherby, United Kingdom, LS23 7FA
| Name | Title | Year Born |
|---|---|---|
| Dr. David Alastair Smith | CEO & Exec. Director | NA |
| Mr. Tony Gardiner | CFO, Company Sec. & Exec. Director | 1971 |
| Ms. Emma Wright | Group In-House Counsel | NA |
| Mr. Michael Vinegrad | Group Communications Director | NA |
| Dr. Matt Johnson | Chief Scientific Officer of Diagnostics | NA |
| Dr. Neil Bell | Chief Devel. Officer of Therapeutics | 1958 |
| Dr. Fiona McLaughlin FSB, Ph.D. | Chief Scientific Officer of Therapeutics Division | 1970 |
| Mr. Marc Green | Head of Product Devel. - Diagnostics | NA |
| Gemma Wilson | Head of QA/RA - Diagnostics | NA |
| Mr. Petros Sarantos | Head of Product Management - Diagnostics | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
UK 
AU
CA
US
NZ
Please wait processing your request...